mekinist
Novartis’ Tafinlar/Mekinist combo improves five-year relapse-free survival in new Phase 3 data
September 17, 2020Research and Development Novartis, Tafinlar, mekinist, melanoma
Novartis has unveiled promising new Phase 3 data for its combination of Tafinlar (dabrafenib) with Mekinist (trametinib) in the treatment …
NICE recommends Novartis combo as first-ever BRAF-targeted therapy for advanced post-surgery melanoma
September 17, 2018Sales and Marketing Cancer, NICE, Novartis, Tafinlar, mekinist, melanoma, pharma
NICE has taken the decision to recommend the first ever first BRAF-targeted therapy for use on the NHS in England …
FDA approves Novartis combo in rare thyroid cancer subtype
May 8, 2018Manufacturing and Production, Sales and Marketing Cancer, FDA, Tafinlar, mekinist, thyroid cancer
The FDA has announced its decision to approve the use of Novartis’ combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in …
Novartis combo expands into lung cancer with EU approval
April 4, 2017Manufacturing and Production, Sales and Marketing NSCLC, Novartis, Tafinlar, mekinist
Novartis has announced that its Tafinlar (dabrafenib) and Mekinist (trametinib) drug combo has been approved by the European Commission (EC) …
Novartis says Phase II data for rare lung cancer showed overall response rate of 63%
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, Novartis, Tafinlar, drug trial, lung cancer, mekinist
Swiss drugmaker Novartis (VTX: NOVN) said combination mid-stage trials for the drug to treat a rare and aggressive form of …
AstraZeneca bags another FDA orphan status in cancer
April 17, 2015Sales and Marketing AstraZeneca, Cancer, FDA, GlaxoSmithKline, mekinist, melanoma, oncology, selumetinib, trametinib
The FDA has granted AstraZeneca’s cancer medicine selumetinib orphan drug designation for the treatment of uveal melanoma. The company will …
Roche wins drug discovery award for Gazyvaro
December 18, 2014Sales and Marketing BPS, British Pharmacological Society, GSK, Gazyvaro, Roche, mekinist
Roche has been named the winner of the 2015 Drug Discover of the Year award by the British Pharmacological Society …
Roche submits melanoma drug to FDA
December 15, 2014Sales and Marketing Cobimeinib, FDA, Roche, Zelboraf, mekinist, melanoma, taflinlar, vemurafenib
Roche has submitted its melanoma drug cobimeinib for review with the FDA as it confirms the results of its Phase …
GSK melanoma drugs beat rival in new study
July 18, 2014Sales and Marketing GSK, Roche, Tafinlar, Yervoy, Zelboraf, mekinist, melanoma
GlaxoSmithKline’s new combination melanoma treatment has bested Roche’s established oncology drug Zelboraf when treating patients with the deadliest form of …
Mekinist shown EU green light
July 7, 2014Sales and Marketing CHMP, Cancer, GSK, Tafinlar, braf, mekinist, melanoma
The European Commission has given GlaxoSmithKline’s melanoma drug Mekinist the thumbs-up following a positive opinion in April from the European …
Mekinist shown green light by CHMP
April 28, 2014Sales and Marketing CHMP, Cancer, GSK, mekinist, oncology, trametinib
GlaxoSmithKline’s melanoma drug Mekinist is virtually nailed on to be given approval in the European Union following a positive opinion …
FDA approves GSK cancer combo
January 14, 2014Research and Development, Sales and Marketing FDA, GSK, Tafinlar, mekinist
US regulators have shown the green light to a combination of two GlaxoSmithKline skin cancer drugs, Mekinist and Tafinlar, to …
GSK files cancer combination
July 10, 2013Sales and Marketing FDA, GSK, Tafinlar, mekinist
GlaxoSmithKline has put in supplemental applications for its Tafinlar/Mekinist combination – a pair of drugs which analysts predict may have …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
